Alpha Lipoic Acid (ALA) for Diabetic Neuropathy

Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial Dan Ziegler, Phillip A. Low, Roy Freeman, Hans Tritschler, Aaron I. Vinik Journal of Diabetes and its Complications; Article in Press Quote: Aims We aimed to analyze the impact of baseline factors on the efficacy of α-lipoic acid (ALA) over 4 years in in the NATHAN 1 trial.

Read the original:
Alpha Lipoic Acid (ALA) for Diabetic Neuropathy

This entry was posted in Podiatry Arena. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *